In December 2020, Relugolix (ORGOVYX) received approval by the FDA for the treatment of adult patients with advanced prostate cancer.

It is a selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR). Unlike most other GnRH modulators, Relugolix is a non-peptide and small-molecule compound and is orally active.

This drug contains 2-aminothiophene-3-carboxylic acid moiety in its backbone.

We have made a set of Building Blocks, which contain Thiophene, 1H-Pyrrole and Furan carboxylic acid parts – the perfect start for your research!